A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the […]
eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck. The ongoing pandemic has underlined the capability for mRNA vaccines as […]
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences from December 2021 to March 2022: BioFIT Digital 7-9 December 2021 Tim Van Assche, VP of Business Development and Alliance will be in attendance. ESMO Immuno-Oncology Online Congress 8-11 […]
